• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雌激素受体α的表达与催乳素垂体瘤预后相关,并支持肿瘤生长中的性别差异。

Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth.

作者信息

Delgrange Etienne, Vasiljevic Alexandre, Wierinckx Anne, François Patrick, Jouanneau Emmanuel, Raverot Gérald, Trouillas Jacqueline

机构信息

Université de Lyon 169372 Lyon, FranceService d'EndocrinologieCHU Dinant-Godinne UCL Namur, Université Catholique de Louvain, 5530 Mont-sur-Meuse, Namur, BelgiumCentre de Neurosciences de LyonINSERM S1028/CNRS UMR 5292, 69372 Lyon, FranceCentre de Recherche en Cancérologie de LyonINSERM U1052/CNRS UMR 5286, 69008 Lyon, FranceService de NeurochirurgieCHU de Tours, et Université François Rabelais, Tours, FranceCentre de Pathologie EstService de NeurochirurgieFédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France

Université de Lyon 169372 Lyon, FranceService d'EndocrinologieCHU Dinant-Godinne UCL Namur, Université Catholique de Louvain, 5530 Mont-sur-Meuse, Namur, BelgiumCentre de Neurosciences de LyonINSERM S1028/CNRS UMR 5292, 69372 Lyon, FranceCentre de Recherche en Cancérologie de LyonINSERM U1052/CNRS UMR 5286, 69008 Lyon, FranceService de NeurochirurgieCHU de Tours, et Université François Rabelais, Tours, FranceCentre de Pathologie EstService de NeurochirurgieFédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France Université de Lyon 169372 Lyon, FranceService d'EndocrinologieCHU Dinant-Godinne UCL Namur, Université Catholique de Louvain, 5530 Mont-sur-Meuse, Namur, BelgiumCentre de Neurosciences de LyonINSERM S1028/CNRS UMR 5292, 69372 Lyon, FranceCentre de Recherche en Cancérologie de LyonINSERM U1052/CNRS UMR 5286, 69008 Lyon, FranceService de NeurochirurgieCHU de Tours, et Université François Rabelais, Tours, FranceCentre de Pathologie EstService de NeurochirurgieFédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France Université de Lyon 169372 Lyon, FranceService d'EndocrinologieCHU Dinant-Godinne UCL Namur, Université Catholique de Louvain, 5530 Mont-sur-Meuse, Namur, BelgiumCentre de Neurosciences de LyonINSERM S1028/CNRS UMR 5292, 69372 Lyon, FranceCentre de Recherche en Cancérologie de LyonINSERM U1052/CNRS UMR 5286, 69008 Lyon, FranceService de NeurochirurgieCHU de Tours, et Université François Rabelais, Tours, FranceCentre de Pathologie EstService de NeurochirurgieFédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France.

出版信息

Eur J Endocrinol. 2015 Jun;172(6):791-801. doi: 10.1530/EJE-14-0990. Epub 2015 Mar 19.

DOI:10.1530/EJE-14-0990
PMID:25792376
Abstract

CONTEXT

A sex difference in the progression of prolactin (PRL) tumors has been disputed for years.

OBJECTIVE

To compare tumor characteristics and postoperative clinical course between men and women, and correlate data with estrogen receptor alpha (ERα (ESR1)) expression status.

DESIGN, PATIENTS, AND METHODS: Eighty-nine patients (59 women and 30 men) operated on for a prolactinoma and followed for at least 5 years were selected. Tumors were classified into five grades according to their size, invasion, and proliferation characteristics. The ERα expression was detected by immunohistochemistry and a score (0-12) calculated as the product of the percentage of positive nuclei and the staining intensity.

RESULTS

We found a significant preponderance of high-grade tumors among men and a lower surgical cure rate in men (23%) than in women (71%). Patients resistant to medical treatment were mainly men (7/8), six of whom showed tumor progression despite postoperative medical treatment, which led to multiple therapies and eventually death in three. The median score for ERα expression was 1 in men (range, 0-8) and 8 in women (range, 0-12) (P<0.0001). The expression of ERα was inversely correlated with tumor size (r=-0.59; P<0.0001) and proliferative activity. All dopamine agonist-resistant tumors and all grade 2b (invasive and proliferative) tumors (from ten men and four women) were characterized by low ERα expression.

CONCLUSIONS

PRL tumors in men are characterized by lower ERα expression, which is related to higher tumor grades, resistance to treatment, and an overall worse prognosis.

摘要

背景

催乳素(PRL)瘤进展中的性别差异多年来一直存在争议。

目的

比较男性和女性的肿瘤特征及术后临床病程,并将数据与雌激素受体α(ERα,ESR1)表达状态相关联。

设计、患者和方法:选取89例接受催乳素瘤手术且随访至少5年的患者(59例女性和30例男性)。根据肿瘤大小、侵袭和增殖特征将肿瘤分为五个等级。通过免疫组织化学检测ERα表达,并计算得分(0 - 12分),得分是阳性细胞核百分比与染色强度的乘积。

结果

我们发现男性中高级别肿瘤明显占比更高,且男性的手术治愈率(23%)低于女性(71%)。对药物治疗耐药的患者主要是男性(7/8),其中6例尽管术后接受了药物治疗仍出现肿瘤进展,这导致了多种治疗,最终3例死亡。男性ERα表达的中位数得分为1分(范围0 - 8分),女性为8分(范围0 - 12分)(P<0.0001)。ERα的表达与肿瘤大小(r = -0.59;P<0.0001)和增殖活性呈负相关。所有对多巴胺激动剂耐药的肿瘤以及所有2b级(侵袭性和增殖性)肿瘤(来自10名男性和4名女性)的特征均为ERα低表达。

结论

男性PRL瘤的特征是ERα表达较低,这与更高的肿瘤分级、治疗耐药性及总体较差的预后相关。

相似文献

1
Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth.雌激素受体α的表达与催乳素垂体瘤预后相关,并支持肿瘤生长中的性别差异。
Eur J Endocrinol. 2015 Jun;172(6):791-801. doi: 10.1530/EJE-14-0990. Epub 2015 Mar 19.
2
Galectin-3 and Estrogen Receptor Alpha as Prognostic Markers in Prolactinoma: Preliminary Results From a Pilot Study.半乳糖凝集素-3 和雌激素受体α 作为催乳素瘤的预后标志物:一项初步研究的结果。
Front Endocrinol (Lausanne). 2021 Jul 12;12:684055. doi: 10.3389/fendo.2021.684055. eCollection 2021.
3
[Pituitary lactotroph adenomas resistant to dopamine agonist treatment: histological and immunohistochemical characteristics].[对多巴胺激动剂治疗耐药的垂体催乳素细胞腺瘤:组织学和免疫组化特征]
Arkh Patol. 2018;80(3):34-39. doi: 10.17116/patol201880334-39.
4
Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line.雌激素受体拮抗剂对泌乳素瘤 MMQ 细胞系生物学行为及生长因子表达的影响。
J Neurooncol. 2011 Apr;102(2):237-45. doi: 10.1007/s11060-010-0326-2. Epub 2010 Aug 11.
5
Expression of estrogen receptor α and growth factors in human prolactinoma and its correlation with clinical features and gender.人泌乳素瘤中雌激素受体α和生长因子的表达及其与临床特征和性别相关性。
J Endocrinol Invest. 2012 Feb;35(2):174-80. doi: 10.3275/7607. Epub 2011 Mar 21.
6
Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up.泌乳素垂体瘤的预后因素:来自 94 例长期术后随访患者的临床、组织学和分子数据。
J Clin Endocrinol Metab. 2010 Apr;95(4):1708-16. doi: 10.1210/jc.2009-1191. Epub 2010 Feb 17.
7
PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.与催乳素细胞多巴胺能调控相关的不同实验性和人催乳素瘤中的PTTG表达
Mol Cancer. 2007 Jan 12;6:4. doi: 10.1186/1476-4598-6-4.
8
Gender-related differences in prolactinomas. A clinicopathological study.催乳素瘤的性别相关差异。一项临床病理研究。
Neuro Endocrinol Lett. 2005 Apr;26(2):152-9.
9
Novel features of tumors that secrete both growth hormone and prolactin in acromegaly.肢端肥大症中同时分泌生长激素和催乳素的肿瘤的新特征。
Neurosurgery. 1994 Aug;35(2):179-83; discussion 183-4. doi: 10.1227/00006123-199408000-00001.
10
Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.泌乳素瘤的临床与组织学相关性,特别提及对溴隐亭的耐药性。
Acta Neurochir (Wien). 2005 Jul;147(7):751-7; discussion 757-8. doi: 10.1007/s00701-005-0498-2. Epub 2005 Mar 14.

引用本文的文献

1
Differential expression of PTEN, pAKT1, pRPS6, and mismatch repair proteins in pituitary neuroendocrine tumors.PTEN、pAKT1、pRPS6和错配修复蛋白在垂体神经内分泌肿瘤中的差异表达
Virchows Arch. 2025 Jul 16. doi: 10.1007/s00428-025-04176-5.
2
Multimodal Model for Non-Invasive Detection of DRD2, SSTR2 and ESR1 Receptor Profiling in Pituitary Neuroendocrine Tumors: A Retrospective Study.垂体神经内分泌肿瘤中DRD2、SSTR2和ESR1受体谱无创检测的多模态模型:一项回顾性研究
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251353305. doi: 10.1177/15330338251353305. Epub 2025 Jun 23.
3
Chromosomal alteration patterns in PitNETs: massive losses in aggressive tumors.
垂体神经内分泌肿瘤中的染色体改变模式:侵袭性肿瘤中的大量缺失。
Endocr Relat Cancer. 2024 Dec 19;32(1). doi: 10.1530/ERC-24-0070. Print 2025 Jan 1.
4
Long term outcomes of pituitary adenomas in Multiple Endocrine Neoplasia type 1: a nationwide study.多发性内分泌腺瘤 1 型中垂体腺瘤的长期预后:一项全国性研究。
Front Endocrinol (Lausanne). 2024 Oct 8;15:1427821. doi: 10.3389/fendo.2024.1427821. eCollection 2024.
5
Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment.泌乳素分泌型垂体腺瘤:发病机制、临床表现和治疗的男性特异性差异。
Front Endocrinol (Lausanne). 2024 Feb 2;15:1338345. doi: 10.3389/fendo.2024.1338345. eCollection 2024.
6
The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations.生长激素和泌乳素分泌型垂体瘤的 ER∝ 表达的预后价值:临床病理相关性。
Int J Mol Sci. 2023 Nov 10;24(22):16162. doi: 10.3390/ijms242216162.
7
Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways.侵袭性 PitNETs 及潜在的靶向治疗:分子和遗传途径的系统综述。
Int J Mol Sci. 2023 Oct 29;24(21):15719. doi: 10.3390/ijms242115719.
8
Endoscopic endonasal surgery for prolactinomas: prognostic factors for disease control and management of persistent disease.经鼻内镜手术治疗泌乳素瘤:疾病控制的预测因素和持续性疾病的处理。
Neurosurg Rev. 2023 Nov 9;46(1):295. doi: 10.1007/s10143-023-02199-7.
9
Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.帕唑帕尼的治疗反应:泌乳素瘤侵袭性的分子异常的病例报告及文献复习。
Front Endocrinol (Lausanne). 2023 Jul 17;14:1195792. doi: 10.3389/fendo.2023.1195792. eCollection 2023.
10
Pituitary tumors and the risk of other malignancies: is the relationship coincidental or causal?垂体瘤与其他恶性肿瘤的风险:这种关系是巧合还是因果关系?
Endocr Oncol. 2022 Dec 22;2(1):R1-R13. doi: 10.1530/EO-21-0033. eCollection 2022 Jan.